Our portfolio company Targovax announces encouraging one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer. The trial is an open label, phase I/II trial of the cancer vaccine TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patients with resected adenocarcinoma of the pancreas. The […]
About Elisabeth K. Andersen
This author has yet to write their bio.Meanwhile lets just say that we are proud Elisabeth K. Andersen contributed a whooping 41 entries.
Entries by Elisabeth K. Andersen
Sent i september hadde Jónas Einarsson en kronikk i Aftenposten der han ber myndigheter og legemiddelindustri komme opp av skyttergravene og snakke med hverandre. Årsaken er at det nåværende systemet for innkjøp og prissetting ikke fungerer, og at pasientene blir de skadelidende. Du kan lese hele kronikken nedenfor. Ikke kjeft. Snakk med hverandre Av […]
Our portfolio company Targovax has over the short time span of eight days managed to be granted not one, but two, US patents for their mutant-RAS neoantigen platform. The first patent is issued to protect Targovax’ mutant-RAS specific neoantigen vaccines, TG01 and TG02, for the treatment of cancer in combination with anti-metabolite chemotherapy. Read more about […]
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to our portfolio company PCI Biotech. This is a major regulatory milestone for the development of the company´s lead product candidate named fimaporfin for the treatment of patients suffering from bile duct cancer. This patient population has no approved treatment alternatives today […]
Radforsk co-hosted three cancer-related events during Oslo Innovation Week and Forskningsdagene. If you missed out, you may watch them now. Together with our partners the Norwegian Cancer Society, Oslo Cancer Cluster, IBM Norway, Cancer Research UK, Norway Health Tech and EAT, we hosted these events. We had great audiences during our three events on the 27th and […]
The progress especially applies for the fimaCHEM programme , with early promising signs of effect in Phase I in treatment of bilde duct cancer.
Reports significant progress, both financially and clinically, in second half 2017 report.
We arrange three seminars during Oslo Innovation Week and Forskningsdagene.
Q2 report shows significant progress in the US market
Second quarter report shows continued solid operational progress.